Your pipeline asset took years to develop. The partnership that was supposed to bring it to market has broken down. Now a tribunal needs to put a number on what it was worth - before the data was in, before regulatory approval, before a single patient was treated.

This is the reality of life sciences arbitration. At the 2026 Paris Arbitration Week, Bird & Bird's Flore Poloni and Mario Subramaniam joined quantum experts from FTI Consulting and an investor from Sofinnova Partners to explore how tribunals approach this challenge - and how the agreements you sign today will shape your position if a collaboration breaks down tomorrow.

From milestone definitions and diligence obligations to the assumptions that drive damages models, the detail of your contracts matters more than you might think.

Read the full article to find out more